Cyclin-dependent kinase 4

2025 Outlook for the Global Breast Cancer Therapeutics Market

Retrieved on: 
Tuesday, May 7, 2019
RTT, Branches of biology, Endocrine system, Breast cancer, Cancer, Aromatase inhibitor, Cyclin-dependent kinase 4, CDK inhibitor, Breast cancer awareness

Treatment of breast cancer is dependent upon various factors such as type of breast cancer, stage of cancer, sensitivity to hormones, patient's age, etc.

Key Points: 
  • Treatment of breast cancer is dependent upon various factors such as type of breast cancer, stage of cancer, sensitivity to hormones, patient's age, etc.
  • The growth of the global breast cancer therapeutics market is attributed to the increasing prevalence of breast cancer, ageing population, rapid changes in lifestyle and increasing public awareness.
  • The report "Global Breast Cancer Therapeutics Market Outlook 2025" provides in-depth analysis of the current scenario, detailed market outlook of the global breast cancer market with market segmentation done across major drug types such as HER2 Inhibitors, CDK4/6 Inhibitors & Aromatase Inhibitors.
  • This information will be helpful in evaluating opportunities in the global breast cancer market.

Global Breast Cancer Therapeutics Market Outlook 2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 3, 2019
Health, Oncology, Pharmaceutical, RTT, Branches of biology, Protein kinase inhibitors, CDK inhibitor, Progonadotropins, Cancer, Cyclin-dependent kinase 4, Breast cancer, Biology, Aromatase inhibitor, PARP inhibitor

The "Global Breast Cancer Therapeutics Market [(By Drug Type - HER2 Inhibitors, CDK4/6 Inhibitors & Aromatase Inhibitors; By Region - North America (The US), Europe (Germany) & Asia Pacific (Japan)] Outlook 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Breast Cancer Therapeutics Market [(By Drug Type - HER2 Inhibitors, CDK4/6 Inhibitors & Aromatase Inhibitors; By Region - North America (The US), Europe (Germany) & Asia Pacific (Japan)] Outlook 2025" report has been added to ResearchAndMarkets.com's offering.
  • The breast cancer therapeutics market has witnessed the advent of innovative novel therapies such as a combination of PARP inhibitors and CDK inhibitors.
  • This report provides in-depth analysis of the current scenario, detailed market outlook of the global breast cancer therapeutics market overall as well as across various geographies.
  • Furthermore, the study encompasses various market-specific growth opportunities in the global breast cancer therapeutics market.

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

Retrieved on: 
Saturday, December 8, 2018
Protein kinase inhibitors, RTT, Cell biology, Chemistry, Cancer, Cyclopentanes, Piperazines, Pyridines, Ribociclib, Metastatic breast cancer, Cyclin-dependent kinase 4, HER2/neu

Kisqali plus endocrine therapy demonstrated consistent efficacy across the MONALEESA trials in patients with and without visceral metastases.

Key Points: 
  • Kisqali plus endocrine therapy demonstrated consistent efficacy across the MONALEESA trials in patients with and without visceral metastases.
  • Kisqali (ribociclib) is the CDK4/6 inhibitor with the largest body of first-line clinical trial evidence demonstrating consistent, superior and sustained efficacy compared to endocrine therapy alone4.
  • Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of Phase III MONALEESA trials.
  • Management of patients with hormone receptorpositive breast cancer with visceral disease: challenges and treatment options.